4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Delivery technologies for the CRISPR-Cas9 gene editing system often require viral vectors, which pose safety concerns for therapeutic genome editing 1 . Alternatively, cationic liposomal components or polymers can be used to encapsulate multiple CRISPR components into large particles (typically >100 nm diameter); however, such systems are limited by variability in loading of the cargo. Here, we report the design of customizable synthetic nanoparticles for the delivery of Cas9 nuclease and a single-guide RNA (sgRNA), enabling controlled stoichiometry of CRISPR components and limiting possible safety concerns in vivo. We describe the synthesis of a thin glutathione (GSH)-cleavable covalently-crosslinked polymer coating, called a nanocapsule (NC), around a pre-assembled ribonucleoprotein (RNP) complex between a Cas9 nuclease and a sgRNA. The NC is synthesized by acrylate-based polymerization, has a hydrodynamic diameter of 25 nm, and can be customized via facile surface modification. NCs efficiently generate targeted gene edits in vitro without any apparent cytotoxicity. Furthermore, NCs produce robust gene editing in vivo in murine retinal pigment epithelium (RPE) tissue and skeletal muscle following local administration. This customizable NC nanoplatform efficiently delivers CRISPR RNP complexes for in vitro and in vivo somatic gene editing.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo

          Efficient intracellular delivery of proteins is needed to fully realize the potential of protein therapeutics. Current methods of protein delivery commonly suffer from low tolerance for serum, poor endosomal escape, and limited in vivo efficacy. Here we report that common cationic lipid nucleic acid transfection reagents can potently deliver proteins that are fused to negatively supercharged proteins, that contain natural anionic domains, or that natively bind to anionic nucleic acids. This approach mediates the potent delivery of nM concentrations of Cre recombinase, TALE- and Cas9-based transcriptional activators, and Cas9:sgRNA nuclease complexes into cultured human cells in media containing 10% serum. Delivery of Cas9:sgRNA complexes resulted in up to 80% genome modification with substantially higher specificity compared to DNA transfection. This approach also mediated efficient delivery of Cre recombinase and Cas9:sgRNA complexes into the mouse inner ear in vivo, achieving 90% Cre-mediated recombination and 20% Cas9-mediated genome modification in hair cells.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The molecular basis of human retinal and vitreoretinal diseases.

              During the last two to three decades, a large body of work has revealed the molecular basis of many human disorders, including retinal and vitreoretinal degenerations and dysfunctions. Although belonging to the group of orphan diseases, they affect probably more than two million people worldwide. Most excitingly, treatment of a particular form of congenital retinal degeneration is now possible. A major advantage for treatment is the unique structure and accessibility of the eye and its different components, including the vitreous and retina. Knowledge of the many different eye diseases affecting retinal structure and function (night and colour blindness, retinitis pigmentosa, cone and cone rod dystrophies, photoreceptor dysfunctions, as well as vitreoretinal traits) is critical for future therapeutic development. We have attempted to present a comprehensive picture of these disorders, including biological, clinical, genetic and molecular information. The structural organization of the review leads the reader through non-syndromic and syndromic forms of (i) rod dominated diseases, (ii) cone dominated diseases, (iii) generalized retinal degenerations and (iv) vitreoretinal disorders, caused by mutations in more than 165 genes. Clinical variability and genetic heterogeneity have an important impact on genetic testing and counselling of affected families. As phenotypes do not always correlate with the respective genotypes, it is of utmost importance that clinicians, geneticists, counsellors, diagnostic laboratories and basic researchers understand the relationships between phenotypic manifestations and specific genes, as well as mutations and pathophysiologic mechanisms. We discuss future perspectives. Copyright 2010 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Journal
                101283273
                34218
                Nat Nanotechnol
                Nat Nanotechnol
                Nature nanotechnology
                1748-3387
                1748-3395
                4 August 2019
                09 September 2019
                October 2019
                09 March 2020
                : 14
                : 10
                : 974-980
                Affiliations
                [1. ]Department of Materials Science and Engineering, University of Wisconsin–Madison, Madison, WI 53715, USA.
                [2. ]Wisconsin Institute for Discovery, University of Wisconsin–Madison, Madison, WI 53715, USA.
                [3. ]Department of Pediatrics, University of Wisconsin - Madison, Madison, WI 53706, USA.
                [4. ]Department of Comparative Biosciences, University of Wisconsin – Madison, Madison, WI 53706, USA
                [5. ]Department of Biomedical Engineering, University of Wisconsin–Madison, Madison, WI 53715, USA.
                [6. ]Department of Ophthalmology and Visual Sciences, University of Wisconsin – Madison, Madison, WI 53706, USA
                [7. ]Department of Chemistry, University of Wisconsin–Madison, Madison, WI 53715, USA.
                Author notes
                [#]

                : These authors contributed equally.

                Author Contributions

                G.C., A.A.A., Y.W., K.S., and S.G. conceived and designed the project; G.C., A.A.A., Y.W., R.X., M.S., S.R., and P.K.S. performed the experiments; all authors analyzed the data; and G.C., A.A.A., Y.W., P.K.S., B.R.P., M.S., K.S., and S.G. co-wrote the paper.

                [* ]Correspondence should be addressed to KS ( ksaha@ 123456wisc.edu ) and SG ( shaoqingong@ 123456wisc.edu )
                Article
                NIHMS1535887
                10.1038/s41565-019-0539-2
                6778035
                31501532
                b12ca080-7203-417c-81f9-991352961cb9

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Nanotechnology
                Nanotechnology

                Comments

                Comment on this article